<DOC>
	<DOCNO>NCT00090857</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Letrozole may effective preventing development recurrence breast cancer postmenopausal woman increase risk develop breast cancer elevate estradiol level . PURPOSE : This randomized phase II trial study well letrozole work prevent breast cancer postmenopausal woman elevate estradiol level .</brief_summary>
	<brief_title>Letrozole Preventing Breast Cancer Postmenopausal Women</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare safety , acceptability , adherence letrozole v placebo postmenopausal woman increase risk development recurrence breast cancer base elevate plasma estradiol level . - Compare effect regimens menopausal symptom ( include hot flush , weight change , sexual functioning , genitourinary effect ) , blood lipid level , marker bone turnover , multidimensional quality life patient treat regimen . Secondary - Determine effect letrozole-induced reduction plasma estradiol level mammographic percent breast density patient . OUTLINE : This pilot , randomize , double-blind , placebo-controlled , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral letrozole daily 1 year . Patients may receive additional oral letrozole daily 4 year . - Arm II : Patients receive oral placebo daily 1 year . Patients may receive oral letrozole daily 5 year . In arm , treatment continue absence unacceptable toxicity diagnosis invasive breast cancer , ductal carcinoma situ , non-breast primary cancer . Quality life assess baseline 3 , 6 , 12 month . PROJECTED ACCRUAL : A total 110 patient ( 73 arm I 37 arm II ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At increase risk development recurrence breast cancer , define estradiol level ≥ 9 pg/mL No evidence suspicious malignant disease , base follow examination : Clinical bilateral breast examination within past 6 month Bilateral* mammogram within 3 month randomization OR within 30 day randomization Pelvic exam normal within past 5 year General physical exam within past 6 month NOTE : *Unilateral mammogram uninvolved breast patient prior invasive breast cancer ductal carcinoma situ ( DCIS ) Bone density scan within 2 standard deviation normal within past 30 day Bone density scan ≥ 2 standard deviation normal allow approve study physician At least 1 breast previously treat radiotherapy surgery ( patient prior invasive breast cancer DCIS ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 35 Sex Female Menopausal status Postmenopausal , define follow criterion : At least 12 month without spontaneous menstrual bleeding Prior hysterectomy bilateral salpingooophorectomy ≥ 55 year age prior hysterectomy without oophorectomy &lt; 55 year age prior hysterectomy without oophorectomy OR status ovary unknown AND folliclestimulating hormone ( FSH ) level postmenopausal range Performance status Normal activity must restrict significant portion day Life expectancy At least 10 year Hematopoietic Complete blood count differential normal Prior benign neutropenia allow provide granulocyte count ≥ 1,500/mm^3 Hepatic Bilirubin normal Alkaline phosphatase normal SGOT SGPT normal Renal Creatinine normal Cardiovascular No uncontrolled cardiovascular disease Other Not pregnant No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No osteoporosis No hyperlipidemia No mental health status result cognitive emotional impairment would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 30 day since prior AND concurrent use follow hormonal agent : Estrogen progesterone replacement therapy Oral contraceptive Raloxifene plasma estrogen receptor modulators ( SERMs ) Androgens ( e.g. , danazol ) Luteinizing hormonereleasing hormone ( LHRH ) analog ( e.g. , goserelin leuprolide ) Prolactin inhibitor ( e.g. , bromocriptine ) Antiandrogens ( e.g. , cyproterone ) More 60 day since prior AND concurrent tamoxifen No prior aromatase inhibitor ( patient prior invasive breast cancer DCIS ) No concurrent phytoestrogenic dietary supplement ( e.g. , soy , ginseng , natural product ) Dietary soy allow Radiotherapy See Disease Characteristics Surgery See Disease Characteristics No prior bilateral mastectomy Other More 60 day since prior treatment invasive breast cancer DCIS More 30 day since prior bisphosphonates calcitonin No prior concurrent participation treatment study invasive breast cancer DCIS No concurrent participation cancer prevention study osteoporosis prevention study involve pharmacologic agent No concurrent calcitonin No concurrent bisphosphonate therapy Concurrent cholecalciferol ( vitamin D ) calcium augment bone mineral density allow</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>